TCBP: TC BioPharm (Holdings) Plc Kompaniya qiymatining sof foydaga nisbati
TC Biopharm (TCBP) kompaniyasining istiqbollari T-hujayra terapiyasi sinovlarining samaradorligiga bog'liq bo'lib, bunda ishlab chiqarishni kengaytirish va dori xavfsizligi asosiy xatarlar bo'lib qolmoqda. Onkologik davolashga bo'lgan talab barqaror va biznesni rivojlantirish faqat ventura moliyalashtirishga bog'liq. GURU.Markets saytidagi ushbu narxlar grafigi PE koeffitsiyenti -0.30 ekanligini ko'rsatmoqda. Ishlab chiqarish sikli qat'iy steril inshootlar qoidalariga va uskunalarning muntazam yangilanishiga asoslangan.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_TCBP_-_TC-Biopharm_-_PE-Multiple "TCBP: TC Biopharm Biznesning o‘zini qoplash muddati 28.04.2023 - 30.09.2024 | 👁️GURU.Markets👁️")
TC BioPharm (Holdings) PLC (TCBP) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati TC Biopharm|TCBP - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati TC BioPharm Ltd|TCBP - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati TC BioPharm (Holdings) Plc|TCBP - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz TC BioPharm|Oraliq likvidlik koeffitsiyenti tcbiopharm.com
- foyda va bozor multiplikatorlari tafsilotlari:
TCBP - Sof foyda|Kelajakdagi foyda TC Biopharm|TCBP - Narx-foyda koeffitsiyenti|Kelajakdagi narx-foyda multiplikatori TC BioPharm (Holdings) Plc|TCBP - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati TC BioPharm (Holdings) Plc|TCBP - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda TC BioPharm|TCBP - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi tcbiopharm.com|TCBP - Joriy yilda bir aksiya uchun foyda o'sishi|Kelgusi yil uchun bir aksiya uchun sof foydaning o'zgarishi prognozi TC Biopharm
Kompaniyaning har tomonlama tahlili:tcbiopharm.com TCBP
TC Biopharm onkologiya markazlari bilan hamkorlik orqali hujayraviy platformalarning organik rivojlanishiga e'tibor qaratadi. P/E koeffitsiyentini tahlil qilish orqali investor aksiyaning bozor qiymatini sof foydaga nisbatan baholaydi. Yuqori koeffitsient daromadning keskin o'sishiga bo'lgan kutilmalarning narxga kiritilganidan dalolat beradi. M&A bitimlari mavjud bo'lmagan taqdirda, ushbu ko'rsatkich klinik ittifoqlarning samaradorligini bevosita aks ettiradi. Uzoq muddatli konsensus koeffitsiyent dinamikasini terapiyaning muvaffaqiyatiga bog'laydi.
Muhim raqobatchilar
P/E multiplikatori argenx.com|Narx-foyda koeffitsiyenti BNTX (BioNTech)|ABVX (ABIVAX) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (ADMA Bio)|Biznesning o‘zini qoplash muddati Protagonist Corp (PTGX)|IMVT - Narxning foydaga nisbati|kiniksa.com (KNSA) - Narx-foyda koeffitsiyenti|Grifols (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotech|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori Aurinia Corp|Narxning foydaga nisbati BioCryst (BCRX)|veratx.com - Narx-foyda multiplikatori|P/E multiplikatori DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Kapitalizatsiyaning foydaga nisbati|ABCL: Narx-foyda koeffitsiyenti|Tourmaline - Bozor narxining sof foydaga nisbati|PGEN: P/E multiplikatori|Narx-foyda koeffitsiyenti pharming.com|Narx-foyda koeffitsiyenti NKTR|UPB: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ZBIO|Narxning foydaga nisbati IMNM (Immunome Bio)|P/E multiplikatori GOSS (Gossamer Bio, Inc.)|Biznesning o‘zini qoplash muddati kalvista.com (KALV)|SEPN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Pieris Pharma|Savara Corp (SVRA) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati RIGL (Rigel Corp)|ANAB (AnaptysBio, Inc.) - P/E multiplikatori|ATXS: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ENGN|P/E multiplikatori RAPT Therapeutics Inc. (RAPT)|Narxning foydaga nisbati Aerovate Therapeutics JBIO|Kompaniya qiymatining sof foydaga nisbati ACRS|KYTX - Narxning foydaga nisbati|tizianalifesciences.com (TLSA) - Narx-foyda koeffitsiyenti|CABA (Cabaletta Bio) - Narx-foyda koeffitsiyenti|VTYX: Bozor narxining sof foydaga nisbati|THTX (Theratechnologies Inc) - P/E multiplikatori|Narx-foyda koeffitsiyenti Avalo Therapeutics Inc (AVTX)|P/E multiplikatori ELDN|Narxning foydaga nisbati AGEN (agenusbio.com)|Narxning foydaga nisbati Climb Bio CLYM|ZURA (Zura Bio Ltd) - Kapitalizatsiyaning sof foydaga nisbati|ATYR - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati ADAG|IMA: P/E multiplikatori|Shattuck Labs - Kompaniya qiymatining sof foydaga nisbati|EQ (Equillium Inc) - P/E multiplikatori|P/E multiplikatori Connect Pharma|Narxning foydaga nisbati Immunic, Inc. (IMUX)|ATRA (atarabio.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati InflaRx IFRX|XFOR - Narx-foyda koeffitsiyenti|Adicet - P/E multiplikatori|CELU - P/E multiplikatori|INMB (INmune Bio Corp) - Narx-foyda koeffitsiyenti|Barinthus Biotherapeutics Corp - Kompaniya qiymatining sof foydaga nisbati|KZR (Kezar Life Sciences) - P/E multiplikatori|sabbiotherapeutics.com (SABS) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Akari Therapeutics Plc (AKTX)|Narx-foyda koeffitsiyenti enlivex.com ENLV|Narxning foydaga nisbati Q32 Bio QTTB|GOVX - Narx-foyda koeffitsiyenti|EDSA: Narx-foyda koeffitsiyenti|IBIO - P/E multiplikatori|carismatx.com (CARM) - Narxning foydaga nisbati|Narx-foyda multiplikatori XTLB|BOLT (Bolt Biotherapeutics Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati HCW Biologics Inc HCWB|Narx-foyda koeffitsiyenti APVO (Aptevo Therapeutics)|Bozor narxining sof foydaga nisbati AIM|P/E multiplikatori ADTX (Aditxt, Inc.)|GRI - Narx-foyda koeffitsiyenti|XRTX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HIND (Vyome Therapeutics)|REVB: P/E multiplikatori|INDP (indaptusrx.com) - Narxning foydaga nisbati|SCNI (Scinai Immunotherapeutics Ltd.) - P/E multiplikatori|CalciMedica Corp (CALI) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Affimed (AFMD)|ALLK - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati HOOKIPA Pharma HOOK|IGMS (IGM Biosciences Inc.) - Kapitalizatsiyaning sof foydaga nisbati|iTeos Therapeutics, Inc. - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati OCEA (Ocean Biomedical Inc)|THRD: P/E multiplikatori
